Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Reparixin (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms FRIDA
- Sponsors Dompe Farmaceutici
- 22 Jul 2022 This trial has been completed in Czech Republic (End Date: 23 March 2020) according to European Clinical Trials Database record.
- 01 Nov 2021 Results (data cutoff: 20 Feb 2019) published in the Breast Cancer Research and Treatment
- 18 May 2020 According to European Clinical Trials Database record, this trial is completed in Poland.